• New quality of life data for ¹⁷⁷Lu-PSMA-617 plus standard of care shows delay in worsening of health-related quality of life (HRQoL) and pain in heavily pre-treated patients with PSMA-positive metastatic castration-resistant prostate cancer (mCRPC) compared to standard of care alone1
   
• US Food and Drug Administration (FDA) granted Breakthrough Therapy designation to ¹⁷⁷Lu-PSMA-617; Submission to FDA and European Medicines Agency on track for 2H21
   
• Novartis committed to …